214 related articles for article (PubMed ID: 16305662)
21. Antigen-specific regulatory T-cell subsets in transplantation tolerance regulatory T-cell subset quality reduces the need for quantity.
Koenen HJ; Joosten I
Hum Immunol; 2006 Sep; 67(9):665-75. PubMed ID: 17002896
[TBL] [Abstract][Full Text] [Related]
22. Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy.
Feng G; Wood KJ; Bushell A
Transplantation; 2008 Aug; 86(4):578-89. PubMed ID: 18724229
[TBL] [Abstract][Full Text] [Related]
23. Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
Nguyen VH; Zeiser R; Negrin RS
Biol Blood Marrow Transplant; 2006 Oct; 12(10):995-1009. PubMed ID: 17084366
[TBL] [Abstract][Full Text] [Related]
24. Use of CFSE to monitor ex vivo regulatory T-cell suppression of CD4+ and CD8+ T-cell proliferation within unseparated mononuclear cells from malignant and non-malignant human lymph node biopsies.
Hilchey SP; Bernstein SH
Immunol Invest; 2007; 36(5-6):629-48. PubMed ID: 18161522
[TBL] [Abstract][Full Text] [Related]
25. Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5.
Le Gallo M; Toutirais O; Montier T; Cabillic F; Bouet F; Delépine P; Lehn P; Jotereau F; Catros V
J Gene Med; 2008 Jun; 10(6):628-36. PubMed ID: 18338820
[TBL] [Abstract][Full Text] [Related]
26. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
[TBL] [Abstract][Full Text] [Related]
27. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
28. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
29. Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application.
Chen LC; Delgado JC; Jensen PE; Chen X
J Immunol; 2009 Sep; 183(6):4094-102. PubMed ID: 19684083
[TBL] [Abstract][Full Text] [Related]
30. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.
Chen A; Liu S; Park D; Kang Y; Zheng G
Cancer Res; 2007 Feb; 67(3):1291-8. PubMed ID: 17283166
[TBL] [Abstract][Full Text] [Related]
31. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
32. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
33. Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells.
Zheng J; Liu Y; Qin G; Chan PL; Mao H; Lam KT; Lewis DB; Lau YL; Tu W
J Immunol; 2009 Sep; 183(6):3742-50. PubMed ID: 19684082
[TBL] [Abstract][Full Text] [Related]
34. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T cells and Toll-like receptors in tumor immunity.
Wang RF; Peng G; Wang HY
Semin Immunol; 2006 Apr; 18(2):136-42. PubMed ID: 16469504
[TBL] [Abstract][Full Text] [Related]
36. Different forms of helper tolerance to carcinoembryonic antigen: ignorance and regulation.
Pickford WJ; Watson AJ; Barker RN
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4528-37. PubMed ID: 17671139
[TBL] [Abstract][Full Text] [Related]
37. Adoptive cell therapy using in vitro generated human CD4+ CD25+ regulatory t cells with indirect allospecificity to promote donor-specific transplantation tolerance.
Jiang S; Tsang J; Lechler RI
Transplant Proc; 2006 Dec; 38(10):3199-201. PubMed ID: 17175221
[TBL] [Abstract][Full Text] [Related]
38. Artificial antigen-presenting cells: artificial solutions for real diseases.
Oelke M; Krueger C; Giuntoli RL; Schneck JP
Trends Mol Med; 2005 Sep; 11(9):412-20. PubMed ID: 16103011
[TBL] [Abstract][Full Text] [Related]
39. Ovarian tumour antigens as potential targets for immune gene therapy.
Kuiper M; Peakman M; Farzaneh F
Gene Ther; 1995 Jan; 2(1):7-15. PubMed ID: 7712335
[TBL] [Abstract][Full Text] [Related]
40. Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Yigit R; Massuger LF; Figdor CG; Torensma R
Gynecol Oncol; 2010 May; 117(2):366-72. PubMed ID: 20144842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
